Pharmaceuticals News and Research

RSS

Best ways for proper disposal of unused medicines

Patients in cities all over the country will learn tomorrow about one of the best ways to avoid today's rampant prescription drug abuse – proper disposal of unused medicines.

15 Nov 2010

Research on P450 compound I may help eliminate toxins

Chemical reactions are happening all over the place all the time on the sun, on the Earth and in our bodies. In many cases, enzymes help make these reactions occur. One family of enzymes, called cytochrome P450s (P450), is important because they help us eliminate toxins.

15 Nov 2010

Sinovac third quarter sales decrease 7% to $9.6 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the three-month and nine-month periods ended September 30, 2010.

15 Nov 2010

Scios announces results of ASCEND-HF trial for ADHF treatment

Scios Inc. announced today that the landmark investigational study of NATRECOR (nesiritide) for the treatment of acutely decompensated heart failure (ADHF), ASCEND-HF, demonstrated no statistically significant difference from placebo in the co-primary endpoints of dyspnea, measured at six and 24 hours, or in the composite of heart failure re-hospitalizations and death during the first 30 days following treatment.

15 Nov 2010

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

Santarus, Inc., a specialty biopharmaceutical company, today announced the commercial U.S. launch of CYCLOSET (bromocriptine mesylate) tablets. CYCLOSET is a prescription drug approved by the U.S. Food and Drug Administration (FDA) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus both as monotherapy and in combination with other oral antidiabetic agents.

15 Nov 2010

Inovio third quarter total revenue decreases from $3.6 million to $1.3 million

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2010.

15 Nov 2010

Dalton Pharma enters co-operation with Lonza to provide integrated chemistry services

Dalton Pharma Services and Lonza jointly announce a co-operation created to provide clients with geographically diversified, fully integrated chemistry services from bench to commercial production of active pharmaceutical ingredients.

15 Nov 2010

Deinobiotics project receives €1.35 million for developing novel antibiotic, antifungal compounds

Deinove, the world's leading specialist in Deinococcus bacteria for biofuels, green chemistry and antibiotics, today announced that its Deinobiotics project is to receive a total of €1.35 million in grants and loans.

15 Nov 2010

ICON, Proteome enter alliance to provide expanded biomarker solutions

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, and Proteome Sciences a leading provider of protein biomarker discovery, validation, and assay development services, today announced the formation of a strategic alliance to provide pharmaceutical companies with an expanded biomarker solution to allow earlier assessments in the development of new medicines.

15 Nov 2010

CEVEC establishes North American subsidiary in Maryland, USA

CEVEC Pharmaceuticals, the developer of a novel human protein expression system derived from amniocytes, announced today the US expansion of it's business by founding a North American subsidiary, CEVEC Pharmaceuticals, Inc., in Potomac, Maryland, USA.

15 Nov 2010

Report documents increase in R&D projects on developing world diseases

Drugmakers are now working on over 100 R&D projects designed to tackle diseases of the developing world and almost 80% of them are being carried out with non-industry partners, according to a report released on Wednesday by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).

15 Nov 2010

POZEN presents PA32540 Phase 1 study results for cardiovascular disease at AHA Session

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced today the results of a Phase 1 study, which reported that PA32540, a novel coordinated-delivery tablet of enteric-coated aspirin (325 mg) and immediate-release omeprazole (40 mg), showed no ex vivo drug-drug interaction with clopidogrel when administered 10 hours apart in healthy patients, based on the study's pre-specified analysis.

15 Nov 2010

Drug industry: Pharmaceutical companies find ways to cope as patents expire; FDA criticized for consulting contracts

There is a simple explanation for most of the mergers and acquisitions in the pharmaceutical world these days the so called Patent Cliff. Simply put, many of the drug industry's biggest earners blockbuster medications that have paid the bills for the last decade are about to lose their patent protections.

15 Nov 2010

TCA Cellular Therapy receives QTDP grant for adult stem cell therapies

TCA Cellular Therapy was recently awarded a Qualifying Therapeutic Discovery Program (QTDP) grant from U.S. Department of Health and Human Services. The program was highly competitive with nearly seven thousand applicants vying for funding.

14 Nov 2010

Exiqon publishes clinical study data on colon cancer

Exiqon A/S today published data from a clinical study that stratifies colon cancer patients into groups of high, medium and low chances of survival which may prove useful for optimizing the treatment of each individual cancer patient.

14 Nov 2010

Astrimmune, London Genetics enter collaboration to plan biomarker identification program

London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, and Astrimmune, which is focused on gastrointestinal cancers, are pleased to announce that they have entered into a collaboration to plan a biomarker identification programme.

14 Nov 2010

AcelRx files registration statement with SEC for public offering of common stock

AcelRx Pharmaceuticals, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by the Company.

14 Nov 2010

Research roundup: Doctors' industry ties; Patient safety and residents' hours; Designing a medical home

Archives of Internal Medicine: Physician Professionalism And Changes in Physician-Industry Relationships From 2004 to 2009 -"During the last 6 years a number of efforts have aimed to reduce, and in some cases eliminate, certain types of physician-industry relationships (PIRs)," including policies "that forbid physicians from accepting samples and receiving food and beverages in offices, limiting company representatives' access to physicians' offices and clinical areas, and banning faculty participation in speaker bureaus and other forms of promotional activity," write the authors.

12 Nov 2010

Derma Sciences net sales for third quarter 2010 increase 17% to $15,096,134

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three and nine months ended September 30, 2010.

12 Nov 2010

Pernix third quarter net sales increase 33% to $7,779,000

Pernix Therapeutics Holdings, Inc., an integrated specialty pharmaceutical company primarily focused on the pediatric market, today announced results for the three and nine months ended September 30, 2010.

12 Nov 2010

Pharmaceuticals News and Research

Best ways for proper disposal of unused medicines

Research on P450 compound I may help eliminate toxins

Sinovac third quarter sales decrease 7% to $9.6 million

Scios announces results of ASCEND-HF trial for ADHF treatment

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

Inovio third quarter total revenue decreases from $3.6 million to $1.3 million

Dalton Pharma enters co-operation with Lonza to provide integrated chemistry services

Deinobiotics project receives €1.35 million for developing novel antibiotic, antifungal compounds

ICON, Proteome enter alliance to provide expanded biomarker solutions

CEVEC establishes North American subsidiary in Maryland, USA

Report documents increase in R&D projects on developing world diseases

POZEN presents PA32540 Phase 1 study results for cardiovascular disease at AHA Session

Drug industry: Pharmaceutical companies find ways to cope as patents expire; FDA criticized for consulting contracts

TCA Cellular Therapy receives QTDP grant for adult stem cell therapies

Exiqon publishes clinical study data on colon cancer

Astrimmune, London Genetics enter collaboration to plan biomarker identification program

AcelRx files registration statement with SEC for public offering of common stock

Research roundup: Doctors' industry ties; Patient safety and residents' hours; Designing a medical home

Derma Sciences net sales for third quarter 2010 increase 17% to $15,096,134

Pernix third quarter net sales increase 33% to $7,779,000

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence